Login to Your Account



ASH 2013

Adaptimmune ‘besieged’ with suitors following its MM data report

By Nuala Moran
Staff Writer

Monday, December 9, 2013
Adaptimmune Ltd. released positive data from the ongoing open-label Phase I/II trial of its autologous T-cell immunotherapy in treating multiple myeloma, reporting a 77 percent complete response rate in the 20 patients treated to date, at 100 days post-infusion of the modified cells. The results, presented yesterday at the American Society of Hematology (ASH) meeting in New Orleans have brought potential partners flocking to Adaptimmune’s door, according to CEO James Noble. "We are pretty much besieged at the moment,” he told BioWorld Today. Oxford, UK-based Adaptimmune’s optimistic news was matched by data from several studies of CTL019, also a modified T-cell immunotherapy, which is owned by Novartis AG.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription